Company Overview and News

0
HCL Infosystems Limited - Updates

2018-06-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500179 HCL-INSYS

19
Market Update: Pharma stocks extend gains with Lupin up 5%; TCS, RIL most active

2018-06-12 moneycontrol
The broader indices are trading on a positive note this Tuesday afternoon with the Nifty trading higher by 47 points at 10,834 and the Sensex added 177 points at 35,661.
500408 500325 AUROPHARMA RELIANCE TTQQY 532714 HINDUNILVR 511389 VIDEOIND IDBLZ HCL-INSYS CADILAHC TATACHEM 532960 JUSTDIAL 532321 535648 532187 532483 RIGD 500696 500179 BJJQY KEC 500770 RLNIY 500034 SBAZ UBNC 524804 INDUSINDBK IBVENTURES CDLYY CNRYY BAJFINANCE ARBQY TATAELXSI CANBK JSTQY

11
Market Update: PSU banks, pharma stocks rally with RIL up 1%; Infosys hits fresh 52-week high

2018-06-12 moneycontrol
The broader indices are trading on a positive note this Tuesday afternoon with the Nifty trading higher by 60 points at 10,848 and the Sensex added 214 points at 35,705.
500408 500325 AUROPHARMA RELIANCE 532714 511389 VIDEOIND HCL-INSYS CADILAHC 532321 532187 RIGD 500179 BJJQY KEC RLNIY 500034 SBAZ UBNC 524804 INDUSINDBK CDLYY BAJFINANCE ARBQY TATAELXSI

0
HCL Infosystems Limited - News Clarification

2018-06-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500179 HCL-INSYS

0
HCL Infosystems Limited - News Clarification

2018-06-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500179 HCL-INSYS

158
Will end of Apple deal bite HCL Infosystems?

2018-06-06 thehindubusinessline
Shares of HCL Infosystems may remain in focus, as its distribution agreement with Apple India will end on March 30, 2019. In 2017, the company had entered into a pact with Apple Inc to distribute Apple products, including the iPhone, in India. The company had reported a loss of ₹143.52 crore for the quarter ended March 2018 on revenues of ₹891.18 crore. For FY18, the loss for HCL Infosystems stood at ₹631.
NDAQ IDFCBANK AAPL 500179 HCL-INSYS 539437

0
HCL Infosystems Limited - AGM/Book Closure

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500179 HCL-INSYS

0
HCL Infosystems Limited - Outcome of Board Meeting

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500179 HCL-INSYS

0
HCL Infosystems scraps sale deal with Axis Investment

2018-04-16 moneycontrol
HCL Infosystems today said it has decided to terminate the deal with Axis Investment Incorporated to sell its subsidiary.
500179 HCL-INSYS

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...